Trimetazidine (Di HCl)
Overview
Moexipril is an oral angiotensin-converting enzyme (ACE) inhibitor and is used to treat hypertension. Like quinapril and ramipril, the active metabolite is produced by deesterification from the prodrug. Moexiprilat (the deesterified form), is about 1000 times active than moexipril itself and antihypertensive activity entirely depends on this metabolite. Prolonged antihypertensive effects allow for once-daily dosing. The dosage range is halved in patients who are taking diuretics or who have renal impairment. It was approved by FDA on April 19, 1995.
Primary Characterstics
belongs to Piperazine. It belongs to Antianginal Agents pharmacological group.The Molecular Weight of Trimetazidine (Di HCl) is 339.30.
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Moexipril's dosage details are as follows:
Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
20 mg | 20 (20) | 8 hourly | PO | |
Paedriatic Dosage (20kg)
|
| | | | Not recommended in this age group |
Neonatal Dosage (3kg)
|
| | | | Not recommended in this age group |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
No data regarding the pathological interferences produced by Trimetazidine (Di HCl) is available.
Back to top
Brands / Trade Names of
Moexipril
Back to top
Manufacturers of
Trimetazidine (Di HCl)
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic